摘要
目的观察早期应用盐酸替罗非班对急性非ST段抬高型心肌梗死患者血小板聚集率及主要心血管不良事件的影响。方法将急性非ST段抬高型心肌梗死患者99例随机分为盐酸替罗非班组(A组)50例及常规治疗组(B组)49例,A组在常规治疗的基础上给予盐酸替罗非班静脉泵入,起始30 min静脉滴注速率为0.4μg/(kg·min),继续以0.1μg/(kg·min)的速率持续静脉泵入,持续72 h。B组仅给予常规治疗,分别于治疗前及治疗72 h后测定血小板聚集率,并且观察随访30 d后主要心血管不良事件及不良反应发生情况。结果与B组比较,A组的血小板聚集率下降更明显(P<0.05)。30 d随访,A组的主要心血管不良事件发生率少于B组,差异有统计学意义(P<0.05),且2组均无严重出血。结论早期应用盐酸替罗非班可降低急性非ST段抬高型心肌梗死患者血小板聚集率,减少主要心血管不良事件的发生率,且安全有效。
Objective To invsetigate the effects of Tirofiban Hydrochloride on platelet aggregation rate and major adverse cardiovascular events （MACE） in patients with non-ST-segment elevation myocardial infarction. Methods 99 patients who were diagnosed as NSTE-AMI were randomly divided into Tiroifban Hydrochloride group （group A, 50 cases） and the routine treatment group （group B, 49 cases）. Group A was treated with Tiroifban Hydrochloride, administered as a dose of 0.4 μg/（kg · min） over a 30-minute period and followed by a 72-hour infusion of 0.1 μg/（kg· min）, in addition to routine treatment. as group B was treated with routine treatment. Platelet aggregation rates were measured before treatment and after 72-hour treatment. Patients were followed up for 30 d, the incidence of major adverse cardiovascular events and the adverse reactions were observed. Results The platelet aggregation rate levels were decreased more obviously in group A after treatment for 72 hours （P〈0.05）. After 30 days, the incidence of major adverse cardiovascular events was lower in group A than that in group B（P〈0.05）. There was no severe haemorrhage in both groups. Conclusion Early use of Tirofiban Hydrochloride can reduce the platelet aggregation rate obveriously in patients with non-ST-segment elevation myocardial infarction, which can reduce the incidence of major adverse cardiovascular events. Tiroifban Hydrochloride is effective and safe in clinical practice.
出处
《医学研究与教育》
CAS
2014年第3期25-28,共4页
Medical Research and Education
关键词
急性非ST段抬高型心肌梗死
盐酸替罗非班
血小板聚集率
主要心血管不良事件
acut-non-ST-segment elevation myocardial infarction
Tiroifban Hydrochloride
platelet aggregation rate
major adverse cardiovascular events
